Latest Content

Inebilizumab gains FDA approval for treating generalized myasthenia gravis, showing significant improvements in muscle strength and steroid reduction.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

The oral medication could be used in gonorrhea that is resistant to antibiotics according to a new phase 3 clinical trial.

The novel biomarker APP performed comparably to Fibrosis-4 overall and showed improved cirrhosis detection in patients with diabetes.

Investigators will test whether adding anodal transcranial direct current stimulation to exergame-based rehabilitation improves short- and long-term cognitive outcomes in 80 adults with multiple sclerosis.

Genetic risk models and variant tools help to guide intensive interventions for high-risk carriers and personalized management for others.

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new disease-modifying therapies.

Adding ianalumab to eltrombopag significantly prolongs time to treatment failure, boosts 6-month response rates, and improves fatigue for adults with primary ITP.